Paratek Pharmaceuticals Stockholders Approve of Acquisition by Novo Holdings

News
Article

Deal includes all company assets.

Shaking hands, Team of lawyers and tax auditors brainstorming together and calculating the balance sheet and historical financial accounts of the company and shareholders. Image Credit: Adobe Stock Images/M+Isolation+Photo

Image Credit: Adobe Stock Images/M+Isolation+Photo

Paratek Pharmaceuticals has officially announced that based on a vote count, its stockholders have approved a merger agreement proposal at a special stockholders meeting, in connection with the previously announced definitive agreement to be acquired by Gurnet Point Capital ("Gurnet Point") and Novo Holdings A/S ("Novo Holdings"). According to a company press release, final results of the voting will be disclosed on Form 8-K filed by Paratek with the U.S. Securities and Exchange Commission.

Paratek’s lead product, Nuzyra (omadacycline), is currently available in the US for the treatment of adult patients with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). In 2019, the company was presented with contract from the U.S. Department of Health and Human Services' (HHS) Biomedical Advanced Research and Development Authority (BARDA), currently valued at $304, aiming to development and US-based manufacturing of Nuzyra for pulmonary anthrax.

Novo Holdings is the controlling shareholder of Novo Nordisk and Novozymes.

Reference: Paratek Pharmaceuticals Announces Stockholder Approval of Acquisition by Gurnet Point Capital and Novo Holdings A/S. Paratek Pharma. September 18, 2023. Accessed September 19, 2023. https://www.paratekpharma.com/investor-relations/press-release

Related Videos
Related Content